TL;DR: Roche and Eli Lilly’s new Alzheimer’s blood test, now FDA-cleared, detects amyloid plaques with over 90% accuracy from a simple blood draw, replacing costly PET scans. It’s a game-changer for early diagnosis, but it’s not a standalone diagnostic—confirmatory CSF or PET may still be needed in borderline cases.
Feature Highlights
The test, marketed as the Elecsys β-Amyloid (1-42) and p-Tau (181) plasma assay, measures two key biomarkers in a single blood sample. Its algorithm combines the amyloid ratio with phosphorylated tau to produce a clear positive or negative result. Key features include: high sensitivity (94%) and specificity (92%), a turnaround time of under 3 hours, and compatibility with standard lab equipment already used in hospitals. Unlike traditional PET scans, this test costs roughly $200–$500 per run, is non-invasive, and can be ordered by primary care physicians—no specialized neurology referral required.
If you want to dig deeper, check out our guide on Notion Tutorial: Build Your Ultimate Second Brain Dashboard.
Comparison to Existing Methods
Compared to amyloid PET scans (which cost $3,000–$5,000 and involve radioactive tracers) or lumbar punctures (which are painful and carry a 1–2% complication risk), this blood test is a massive leap in accessibility. However, it trails the accuracy of CSF analysis (which exceeds 95% in both metrics) and cannot measure tau tangles directly—only their phosphorylated precursor. In head-to-head trials, the Roche/Lilly test outperformed C₂N Diagnostics’ PrecivityAD by roughly 6% in specificity, but it still requires a second confirmatory test for patients whose results fall in the “gray zone” (about 15% of cases). For context, the test is designed for people over 55 with mild cognitive impairment, not for asymptomatic screening.
Call-to-Action
If you or a loved one are experiencing memory lapses, ask your doctor today whether this blood test is right for you. Early detection gives you up to 10 extra years to plan treatment, enroll in clinical trials, or make lifestyle changes that slow decline. Don’t wait for a PET scan—request the Elecsys panel at your next checkup and take control of your cognitive future.
FAQ
Q: Is this blood test covered by Medicare or private insurance?
A: Yes, most major private insurers and Medicare Part B cover it when ordered by a physician for patients with documented cognitive impairment. However, copays can range from $0 to $150 depending on your plan.
Q: Can a negative result rule out Alzheimer’s disease completely?
A: No—it rules out amyloid pathology with 94% certainty, but rare non-amyloid forms of dementia (e.g., frontotemporal or vascular) may still exist. A negative result should be combined with a neurological exam to rule out other causes.
Q: How soon can I get results after the blood draw?
A: Most labs return results within 2–3 business days. The test requires a standard venous blood draw (no fasting needed), and samples are stable for up to 7 days if refrigerated, allowing for centralized processing.
Leave a Reply